Evidence map›Paper›PMID 40876346›Full record

ArticleParkinsonism & related disorders2025

Relationship between VMAT2-PET and DAT-SPECT caudate binding and Parkinson's disease cognitive decline.

Mohammad Hamo, Nicole Anyanwu, Isabel Long, Rishabh Gupta, Rocio Bermudez, Deeptha Subramanian, Helen Qian, Kaltra Dhima, Sarah K Bick

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Parkinsonism & related disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mohammad HamoHeersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
Nicole AnyanwuSpelman College, Atlanta, GA, USA.
Isabel LongDepartment of Neurosurgery, Vanderbilt University Medical Center, Nashville, TN, USA.
Rishabh GuptaUniversity of Minnesota-Twin Cities Medical School, Minneapolis, MN, USA.
Rocio BermudezDepartment of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, NC, USA.
Deeptha SubramanianDepartment of Neurosurgery, Vanderbilt University Medical Center, Nashville, TN, USA.
Helen QianDepartment of Neurosurgery, Vanderbilt University Medical Center, Nashville, TN, USA.
Kaltra DhimaDepartment of Psychiatry, University of Texas Southwestern Medical Center, USA.
Sarah K BickDepartment of Neurosurgery, Vanderbilt University Medical Center, Nashville, TN, USA; Department of Biomedical Engineering, Vanderbilt University, Nashville, TN, USA; Department of Psychiatry, Vanderbilt University Medical Center, Nashville, TN, USA. Electronic address: sarah.bick@vumc.org.

Funding

Neurophysiology of Reward Signaling in Parkinson's DiseaseK08NS140767 · NINDS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Sarah Kathleen Bick · 2025 to 2026
$381k
NINDS NIH HHS K08 NS140767
6 · The paper itself

Abstract

introductionDopamine transporter (DAT) imaging can help diagnose Parkinson's disease (PD), and decreased caudate binding predicts cognitive decline. Studies suggest vesicular monoamine transporter type 2 (VMAT2) imaging is more sensitive in detecting striatal changes associated with PD motor symptoms. Our hypothesis is that lower VMAT2 caudate binding is correlated with future cognitive decline in PD.

methodsWe utilized clinical and imaging data from the Parkinson's Progression Markers Initiative (PPMI). We evaluated the relationship between baseline VMAT2 and DAT caudate binding and future change in Montreal Cognitive Assessment (MoCA) score using linear regression. To evaluate localization of findings we performed similar analysis with VMAT2 and DAT putamen and most and least affected caudate binding. We also categorized patients into groups of normal and reduced VMAT2 and DAT caudate binding and compared baseline and follow up characteristics between groups.

resultsAmong 54 subjects with follow up data, baseline VMAT2 caudate binding correlated with change in MoCA score, while DAT did not (r = 0.280, p = 0.0164 and r = 0.189, p = 0.410 respectively). Baseline VMAT2 putamen binding also correlated with change in MoCA score (p = 0.0236, r = 0.23). Reduced VMAT2 caudate binding groups had higher motor severity score at baseline and lower cognitive scores on follow-up (p = 0.0015), while DAT did not (p = 0.174). Patients with reduced VMAT2 caudate but not putamen binding had significantly greater decline in MoCA score (caudate p = 0.0015, putamen p = 0.179).

conclusionReduced caudate VMAT2 binding may predict future cognitive decline, and in our patient population, was more sensitive than caudate DAT binding in predicting the magnitude of decline.

Indexed as

Caudate NucleusCognitive DysfunctionDopamine Plasma Membrane Transport ProteinsParkinson DiseaseVesicular Monoamine Transport ProteinsAgedFemaleHumansMaleMiddle AgedPositron-Emission TomographyTomography, Emission-Computed, Single-PhotonDopamine Plasma Membrane Transport ProteinsSLC18A2 protein, humanVesicular Monoamine Transport ProteinsCognitive declineCognitive impairmentDopamine transporterMontreal cognitive assessmentParkinson's diseaseVesicular monoamine transporter type 2

Identifiers

PMID40876346
PMCPMC13312322

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.